Is QIAGEN NV overvalued or undervalued?

As of 9 September 2025, the valuation grade for QIAGEN NV has moved from expensive to fair, indicating a more favorable assessment of its market position. The company appears to be fairly valued at this time. Key valuation ratios include a P/E ratio of 20, an EV to EBIT of 19.95, and a PEG ratio of 0.59, which suggests that the stock is reasonably priced relative to its earnings growth potential.
In comparison to peers, QIAGEN NV's P/E ratio of 24.20 is higher than Hologic, Inc.'s P/E of 21.83, but lower than The Cooper Companies, Inc.'s P/E of 34.28, indicating a competitive standing within the industry. Despite this fair valuation, QIAGEN NV has underperformed against the S&P 500 over multiple periods, with a 5-year return of -14.74% compared to the S&P 500's 96.61%, highlighting potential concerns regarding its growth trajectory.